Blood sugar tightrope: can intensive control help stem cell patients?

NCT ID NCT00582036

Terminated Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether keeping blood sugar very tightly controlled (goal of 110 mg/dL) using continuous insulin could help people undergoing stem cell transplants. The researchers wanted to see if it would lower death rates, reduce infections, and shorten hospital stays. However, the trial was stopped early and only included 11 participants, so we cannot draw strong conclusions from it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Regular insulin
What this could lead to: If it worked, this approach could reduce infections and shorten hospital stays for stem cell transplant patients.
What could go wrong: The trial was terminated early and enrolled only 11 people, so results are very limited. Tight glucose control can also cause dangerously low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC STEM CELL TRANSPLANTATION HYPERGLYCEMIA

Contacts and locations

Locations

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.